News Bayer's regorafenib kicks off brain cancer platform trial Bayer has become the first pharma company to take part in a new platform trial designed to find new treatments for brain cancer.
News BMS’ Opdivo fails late-stage brain cancer test Bristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new types of cancer.
Views & Analysis An echo through brain cancer’s empty pipeline Brain tumours kill more people aged under 40 than any other cancer, yet there have been no new treatments for more than a decade. What’s more, there are still none in the pipeline.
News Certain brain tumours could respond to immunotherapy Some brain tumours may respond to immunotherapy after all, according to a new study.
Views & Analysis Kick-starting innovation in Glioblastoma Can risk-sharing and real-world evidence can provide traction in treating the brain cancer Glioblastoma?
News Head patch device Optune improves brain cancer survival Median overall survival improved from 15 months to 21 months when combined with chemotherapy.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.